Stamford Therapeutics Consortium

Osteoarthritis

Stamford Therapeutics Consortium is currently conducting a Phase III study on osteoarthritis of the hip or knee sponsored by Pfizer.

Summary: The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis.

For More Information Please Contact:
Judy Dalgin (Site Manager)
email: jdalgin@stctrials.com
telephone: 203-325-8529


Eligibility:


• Ages Eligible for Study: 18 Years to 75 Years

• Genders Eligible for Study: Both

• Accepts Healthy Volunteers: No


Inclusion Criteria:


• Osteoarthritis of the knee or hip according to Kellgren-Lawrence x-ray grade of 2


Exclusion Criteria:

• Pregnancy or intent to become pregnant

• BMI greater than 39

• Other severe pain, significant cardiac, neurological or psychiatric disease

Stamford Therapeutics Consortium

Website Designed And Maintained By Skye Communication, LLC.